Comparative Pharmacokinetics and Safety of Imrecoxib, a Novel Selective Cyclooxygenase-2 Inhibitor, in Elderly Healthy Subjects

• Published in: Drug design, development and therapy Vol. 16; pp. 3865 - 3876
• Main Authors: Yang, Ling, Shen, Qi, Hu, Chao, Wang, Ying, Zhu, Xiaohong, Shu, Shiqing, Luo, Zhu
• Format: Journal Article
• Language: English
• Published: Macclesfield Dove Medical Press Limited 01.01.2022; Taylor & Francis Ltd; Dove; Dove Medical Press
• Subjects: Acids; Aged; Alcohol; Analysis; Antibodies; Bioavailability; Biochemistry; Chromatography; Clinical trials; COX-2 inhibitors; Cyclooxygenase-2; cyclooxygenase-2 inhibitor; Drug dosages; elderly; Electrocardiography; Hematology; Hepatitis; imrecoxib; Inflammation; Laboratories; Metabolism; Metabolites; Older people; Oral administration; Original Research; Osteoarthritis; Pain; Pharmaceuticals; Pharmacokinetics; Pharmacology; Plasma; Safety; Urinalysis; China; United States > US

Background: Imrecoxib is a novel and moderately selective cyclooxygenase-2 inhibitor with properties of anti-inflammation and alleviating pain, which is widely applied in osteoarthritis patients. The pharmacokinetic data supporting imrecoxib's rational use in elderly population are not availabl...